Psoriasis Therapies and the Risk of Cutaneous Malignancy

Abstract

Psoriasis is a complex inflammatory disease that affects approximately 3.2% of US adults 1 . Chronic inflammation associated with psoriasis is a risk factor for multiple medical comorbidities, including malignancy. Several studies have revealed an increased ABSTRACT Background: Systemic therapies for moderate-to-severe psoriasis target the dysregulated inflammatory response. However, their immunomodulatory properties may also contribute to carcinogenesis, leading to an increased risk of cutaneous malignancy in patients exposed to systemic agents.